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Ross II operation, because the left ventric-
ular end of the graft can be used as a
margin for suturing to the mitral annulus. A
sewing cuff around the graft is unneces-
sary. However, stronger lengthwise rein-
forcement is essential to maintain the shape
of the autograft. It seems to me that the
pulmonary autograft flattened out in Dr
Tireli’s patient, and that the consequent left
ventricular inflow obstruction caused pul-
monary congestion because the lengthwise
reinforcement of the pulmonary autograft
failed. A semi-flexible Dacron graft is
probably an inappropriate choice of mate-
rial for the external cylinder of the pulmo-
nary autograft in pediatric patients. A semi-
rigid graft designed to resist elongation
both lengthwise and crosswise is more suit-
able for reinforcing the pulmonary au-
tograft. At present, I believe that a non-
stretch-type polytetrafluoroethylene graft
(Gore-Tex; W. L. Gore & Associates, Inc,
Flagstaff, Ariz) is the best material. Be-
cause the left ventricular end (the pulmo-
nary commissure end) of the graft is anas-
tomosed to the mitral annulus in the top hat
method, varus deformity of the pulmonary
commissures and subsequent narrowing of
the orifice are prevented. If the left atrial
end of the graft (the pulmonary annular
end) is anastomosed to the mitral annulus,
left ventricular outflow obstruction is infal-
lible, because the implanted graft protrudes
into the left ventricle. In addition, varus
deformity of the pulmonary commissures
because of the left ventricular inner pres-
sure is infallible in the absence of a rigid
commissural stent.
A great advantage of our technique,2 in
which a sewing cuff made of a polytetra-
fluoroethylene felt is anastomosed to the
middle portion of the polytetrafluoroethyl-
ene (Gore-Tex) graft, is that neither end of
the graft protrudes into the left atrium or
the left ventricle. Furthermore, because of
the sewing cuff, the polytetrafluoroethyl-
ene (Gore-Tex) graft is fairly close to the
left ventricular end (the pulmonary com-
missure end) of the graft and is tightly
anastomosed to the mitral annulus. There-
fore, varus deformity of the pulmonary
commissure is prevented in the absence of
a rigid stent. The polytetrafluoroethylene
(Gore-Tex) external cylinder ensures an
adequate neo-mitral orifice.
In conclusion, although there are some
technical difficulties, I believe that the
Ross II operation is a useful surgical option
for pediatric patients with a narrow mitral
annulus. With our technique, the Ross II
operation is suitable for infants with a nar-
row left atrium or atrioventricular septal
defect and left ventricular outflow obstruc-
tion.
Masaaki Yamagishi, MD, PhD
Department of Pediatric Cardiovascular
Surgery
Children’s Research Hospital
Kyoto Prefectural University of Medicine
Kyoto, Japan
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Intraoperative hematocrit and
cardiopulmonary bypass
To the Editor:
I read with interest the article by Habib and
associates1 in the June issue of the Journal
concerning the role of the lowest hemato-
crit as the predictor variable on early and
late postoperative outcomes. It is important
to maintain the hematocrit within the nor-
mal range and avoid extremes. The mere
effect of such a strong association begs for
a prospective randomized study, as stated
by the authors. However, their discussion
and conclusion based on the large number
of retrospective patients are incomplete. In
the field of cardiovascular epidemiology,
anemia occurs in 15% to 55% of patients
with chronic heart failure.2 However, it is
unknown whether a strong association of
anemia and heart failure has any temporal
and causal relation, that is, whether anemia
precedes and leads to heart failure.
Nonetheless, the authors do not mention
the characteristics and prevalence of heart
failure in the baseline data. An argument
for expanded plasma volume occurring in
acute heart failure, seen in decompensated
heart failure, might contribute to low he-
moglobin concentrations. Such a feature is
not uncommon in patients undergoing non-
percutaneous transluminal coronary angio-
plasty in our era.
It would seem intuitive to deduct that
patients who undergo off-pump cardiac by-
pass surgery with minimal blood loss have
less activation of the inflammatory cascade
from the bypass circuit and do better. How-
ever, given the already available data from
randomized trials, no difference exists be-
tween the 2.3 This suggests a minimal role
for the intraoperative spectrum of hemato-
crit in off-pump surgery. Another impor-
tant question that was not answered was
whether aprotinin was given consistently,
because this drug can also modify patients’
outcomes.4
Habib and colleagues1 gave no informa-
tion about the mean number of grafts per
patient, perioperative blood loss, blood-
saving techniques, and “transfusion trig-
ger.” These issues are important because
there is a dose-dependent association be-
tween blood transfusion and the develop-
ment of severe postoperative infection and
death in patients undergoing cardiac sur-
gery.5
Despite this omission, the overall in-
hospital mortality rate is slightly higher
than that reported for a similar series of
2,569 patients undergoing coronary artery
bypass grafting in whom the “transfusion
trigger” during cardiopulmonary bypass
(CPB) was a packed-cell volume of less
than 20% and mortality was defined as
death during the hospital stay or within 30
days of surgery (3.6% vs 2.79%).5
Was the pump primed with blood? Ad-
ministration of blood during CPB may be-
gin a cascade of events that contributes to
postoperative. Thus, whenever possible,
preoperative pharmacologic therapy, but
not transfusional, treatment of anemia
should be used.
Also, the authors probe the data to de-
termine any association of anemia and late
mortality. It is interesting that the authors
do not report the reason for patient death.
Because the case mix of death is important,
if cardiovascular death was the cause, did
any of the patients who received more
blood or had the lowest hematocrit have a
lower graft patency in the short and long
term?
Finally, according to the range of abso-
lute differences in the perioperative hemat-
ocrit shown in Table 1 of the article
(difference between preoperative and post-
operative CPB hematocrits; range 12%-
15.2%), it would seem more reasonable to
use this parameter than individual values if
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the conclusion of increased hemodilution
severity is CPB based. If the data are rean-
alyzed on the basis of the difference be-
tween preoperative and postoperative CPB
hematocrits, it may be more important that
a decrease in hematocrit of more than ap-
proximately 10% during bypass is associ-
ated with a worse prognosis than discrete
values.
Jeffrey H. Shuhaiber, MD
Department of Surgery
University of Illinois at Chicago
Chicago, Ill
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Reply to the Editor:
We thank Dr Shuhaiber for his interest in
our recent article in the Journal.1 We are
encouraged that he concurs with us that
low extremes of hematocrit during cardio-
pulmonary bypass (CPB) should be
avoided and that the strong associations we
reported between excessive hemodilutional
anemia during bypass and adverse patient
outcomes argue for a prospective study. He
also requested methodologic clarifications
and presented several comments that are
worthy of addressing.
Our 5000-patient CPB retrospective se-
ries1 (1994–2000) reflects a population in
whom asanguinous rather than blood prime
fluid was used. In a very small fraction of
patients (anemic patients with low red
blood cell volume), blood may have been
added to the prime at the onset of CPB.
These are included as intraoperative trans-
fusions. Aprotinin was used relatively in-
frequently (7%), and we believe it had
little bearing, if any, on the reported find-
ings. Standard intraoperative cell-saving
methods were used routinely, and saved
cells were returned to patients during or
immediately after CPB. Hemoconcentra-
tion during CPB was used in 16% of pa-
tients.
Perioperative blood-loss amounts were
not prospectively documented in our data-
base and were not reported. Alternatively,
excessive bleeding requiring re-exploration
(Figure 1 and Table 4 of reference 1) and
transfusions (Figure 3 and Table 4 of ref-
erence 1) were reported.1 The “transfusion
trigger” was not rigidly controlled during
the 7-year period of this retrospective se-
ries, and this threshold may have varied
slightly among surgeons and depended on
the patient age and clinical status. We be-
lieve, however, that these variations do not
diminish the clear and obviously strong
relationship between nadir CPB hematocrit
and transfusion rates (Figure 3 of reference
1).
As we reported,1 low pre-CPB hemato-
crit is an important predictor of increased
hemodilution during standard CPB (Table
2 of reference 1), but a history of conges-
tive heart failure (documented in 9% of
patients in this series) is not. Notably, pa-
tients with acute heart failure that is asso-
ciated with anemia as the result of compen-
satory plasma volume expansion almost
never undergo operation in our practice.
Such patient conditions are usually medi-
cally reversed before surgery. Alterna-
tively, intraoperative fluid infusions by an-
esthesia and preoperative blood donation
may lead to substantial plasma volume ex-
pansion that can contribute to the extent of
hemodilution during CPB and should be
carefully considered.
Dr Shuhaiber refers to the randomized
prospective study by Puskas and col-
leagues,2 which compares off-pump and
on-pump bypass operations in 200 patients
and states that the role of intraoperative
hematocrit in off-pump CABG is minimal
because little or no differences in outcomes
are reported. In responding to this point, it
is important to note that off-pump and on-
pump CABG procedures are different in
many ways, one of which is hemodilution
as the result of mixing the patient’s blood
with prime fluid. Although it is true that
Puskas and colleagues reported generally
similar in-hospital and 30-day mortalities,
their data partially support several of our
findings.1 Indeed, they reported less he-
modilution, less transfusion requirements,
less coagulopathy, earlier extubation, de-
creased hospital stays, and less myocardial
injury (cardiac enzyme levels) for their pa-
tients undergoing off-pump CABG versus
on-pump CABG. These results are all in
concert with our findings. The fact that no
significant differences in other important
outcome measures (including mortality)
were found may be partially attributable to
the size of the series.
For the 3,800 isolated patients undergo-
ing CABG in this series, the mean number
of grafts per patient was 3.1  1.0. More-
over, as we report in Results1 on page
1441, operative mortality (defined as in
hospital or out of hospital within 30 days of
surgery) for isolated CABG was 2.4% (90/
3800), a rate slightly lower (rather than
higher) than that cited by Dr Shuhaiber in
the CABG series.3 The 3.6% operative
mortality that he reports reflects the overall
rate for all 5,000 patients, including pa-
tients undergoing valve and combined
CABG and valve operations.
As we stated in our article,1 late mor-
tality follow-up was based on queries of the
Social Security Death Index Database, in
which the cause of death is not available;
thus we could not report the relationship
between hematocrit on CPB and late car-
diovascular death. Nonetheless, Dr Shu-
haiber’s questions about whether graft fail-
ure in CABG is linked to the extent of
hemodilutional anemia or transfusions is
clearly important and worthy of separate
future investigation that is well outside the
scope of our study.
Intuitively, Dr Shuhaiber’s proposition
that the decrease in hematocrit should be
used as the independent (or predictor) vari-
able rather than the actual low hematocrit is
appealing. However, the extent of hemodi-
lution on CPB is multifactorial, as we re-
ported in Table 2.1 Also, our1 and De-
Foe’s4 data clearly demonstrated that a
decrease of 10% or 15% in hematocrit is
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 4 1227
